(Q33958376)

English

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

irritable bowel syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

P Schoenfeld

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

M Pimentel

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

L Chang

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Lembo

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

W D Chey

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J Yu

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

C Paterson

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

E Bortey

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

W P Forbes

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

3 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1161-1168

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Current state of Clostridium difficile treatment options

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Current status of Clostridium difficile infection epidemiology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Evaluation of harm in the pharmacotherapy of irritable bowel syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Antibiotics for the treatment of irritable bowel syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Rifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Rifaximin therapy for patients with irritable bowel syndrome without constipation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Rifaximin treatment in hepatic encephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

An evidence-based position statement on the management of irritable bowel syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Functional bowel disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112801

5 July 2018

Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12735

21 January 2018

Rifaximin in the treatment of recurrent Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12735

21 January 2018

Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12735

21 January 2018

Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24697851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/24697851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibiotic therapy for the irritable bowel syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/24697851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24697851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/APT.12735

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33958376&oldid=1989406578"